Trifosmin

Trifosmin

SCHEMBL291309

COCCCP(CCCOC)CCCOC

nearest known ligand 0.35

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.35
GAA P10253 1/20 0.32
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7142674 0.97 ALDH1A1 (0.33) ALDH1A1GAATSHR
Trifosmin SCHEMBL8406572 0.97 ALDH1A1 (0.33) ALDH1A1GAATSHR
SCHEMBL5270639 0.90 ALDH1A1 (0.39) ALDH1A1GAATSHR
SCHEMBL18486622 0.88 ALDH1A1 (0.42) ALDH1A1GAA
SCHEMBL18486666 0.88 ALDH1A1 (0.42) ALDH1A1GAA
SCHEMBL18486498 0.88 ALDH1A1 (0.42) ALDH1A1GAA
SCHEMBL18486516 0.88 ALDH1A1 (0.42) ALDH1A1GAA
SCHEMBL13678756 0.87 ALDH1A1 (0.33) ALDH1A1GAATSHR
SCHEMBL4967863 0.81 PIK3CD (0.30) ALDH1A1
SCHEMBL6230430 0.79 LPAR3 (0.40) ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2981560-B1 CURING OF LIQUID THERMOSETTING RESINS REICHHOLD LLC 2 (US) 2021-10-13 EP claimed
EP-2981560-A1 CURING OF LIQUID THERMOSETTING RESINS Reichhold, Inc. (US) 2016-02-10 EP claimed
US-9068045-B2 Curing of liquid thermosetting resins REICHHOLD, INC. (US) 2015-06-30 US claimed
WO-2014165425-A1 CURING OF LIQUID THERMOSETTING RESINS REICHHOLD, INC. (US) 2014-10-09 WO claimed
US-20140303315-A1 CURING OF LIQUID THERMOSETTING RESINS Polynt Composites USA Inc. 2014-10-09 US claimed
EP-0625054-B1 RADIOPHARMACEUTICAL KITS STABILISED BY CYCLODEXTRINS MALLINCKRODT INC (US) 2007-11-14 EP claimed
EP-1598053-B1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres OREAL (FR) 2006-12-20 EP claimed
EP-1690552-A2 Radiopharmaceutical kits stabilised by means of cyclodextrins Mallinckrodt Inc. (US) 2006-08-16 EP claimed
EP-1598053-A1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres L'OREAL (FR) 2005-11-23 EP claimed
US-20050251928-A1 Method for stripping artificial color from keratin fibers L'OREAL (FR) 2005-11-17 US claimed
EP-0692978-A4 RADIOPHARMACEUTICAL FORMULATIONS HAVING NON-STANNOUS REDUCTANTS MALLINCKRODT MEDICAL INC (US) 1998-05-06 EP claimed
EP-0625054-A4 STABILIZED RADIOPHARMACEUTICAL KITS. MALLINCKRODT MEDICAL INC (US) 1996-04-17 EP claimed
EP-0692978-A1 RADIOPHARMACEUTICAL FORMULATIONS HAVING NON-STANNOUS REDUCTANTS MALLINCKRODT MEDICAL, INC. (US) 1996-01-24 EP claimed
EP-0625054-A1 STABILIZED RADIOPHARMACEUTICAL KITS MALLINCKRODT MEDICAL, INC. (US) 1994-11-23 EP claimed
WO-1994022496-A1 RADIOPHARMACEUTICAL FORMULATIONS HAVING NON-STANNOUS REDUCTANTS MALLINCKRODT MEDICAL, INC. (US) 1994-10-13 WO claimed
EP-0563328-A1 ?99m Tc(III) MYOCARDIAL IMAGING AGENTS AND METHOD OF USE MALLINCKRODT MEDICAL, INC. (US) 1993-10-06 EP claimed
WO-1993015765-A1 STABILIZED RADIOPHARMACEUTICAL KITS MALLINCKRODT MEDICAL, INC. (US) 1993-08-19 WO claimed
WO-1992011040-A2 99mTc(III) MYOCARDIAL IMAGING AGENTS AND METHOD OF USE MALLINCKRODT MEDICAL, INC. (US) 1992-07-09 WO claimed
US-5112595-A Diaminoalkyldifuranones and phosphine ligands with technetium for imaging MALLINCKRODT MEDICAL, INC. (US) 1992-05-12 US claimed
US-5112594-A Diaminoalkyldifuranones and phosphine ligands with technetium for imaging MALLINCKRODT MEDICAL, INC. (US) 1992-05-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050251928-A1 Method for stripping artificial color from keratin fibers KRT18, DSG1, JUP ALDH1A1 4512/4885GAA 3758/4885TSHR 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.